Table 1 Basic characteristics of included studies in the meta-analysis
From: The impact of lymphadenectomy on ovarian clear cell carcinoma: a systematic review and meta-analysis
Author | Year | Country; Study period | Group(No.) | Definition | Age | FIGO stage (patient No) | Adjuvant chemotherapy | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|
Suzuki at el. | 2008 | Japan; 1986–2006 | LA 104(50.7%) | Pelvic and para-aortic lymphadenectomy | 52 (30–75) | Ia–b:19(18.3%) Ic: 76 (73.0%) IIa–b: 9(8.7%) | Platinum-based 34 (32.7%) TP 54 (51.9%) Others 1 (1.0%) None 15 (14.4%) | 49.6 |
|  |  |  | No-LA 101(49.3%) | With or without sampling of lymph nodes | 51 (32–75) | Ia–b:27(26.7%) Ic: 67 (66.3%) IIa–b: 7(7.0%) | Platinum-based 49 (48.5%) TP 34 (33.7%) Others 2 (1.9%) None 16 (15.8%) | 49.2 |
Takano at el. | 2009 | Japan; 1992–2002 | LA 124(67.3%) | Pelvic and para-aortic lymphadenectomy | NA | Ia: 32 (26%) Ic: 92 (74%) | Paclitaxel + platinum 51 (41%) Others* 64 (52%) None 9 (7%) | 49 (5–130) |
|  |  |  | No-LA 65(32.7%) | Only lymph node exploration or sampling | NA | Ia: 13 (20.0%) Ic: 52 (80.0%) | Paclitaxel + platinum 20 (31%) Others* 38 (58%) None 6 (10%) | 57 (5–150) |
Magazzino at el. | 2011 | Italy; 1991–2007 | LA 115(47.9%) | Pelvic lymphadenectomy51 pelvic and para-aortic lymphadenectomy 64 | 56 (29–83) | I: 108 (45%) II: 30 (12.5%) III: 81 (33.7%) IV: 16 (6.6%) Not available: 5 (2.0%) | Platinum-based with taxane 127 (52.9%) Without taxane 92 (38.3%) None 21 (8.75%) | 30.1 (1.4–126.6) |
| Â | Â | Â | No-LA 125(52.1%) | Not performed | Â | Â | Â | Â |
Mahdi at el. | 2013 | USA; 1988–2007 | LA 1298(70.7%) | Pelvic and para-aortic lymphadenectomy | 56.2 | Stage I | NA | NA |
| Â | Â | Â | No-LA 538(29.3%) | Not performed | 54.7 | Â | NA | NA |
Yamazaki at el. | 2018 | Japan; 1995–2015 | LA 91(71.7%) | Pelvic lymphadenectomy12 pelvic and para-aortic lymphadenectomy 79 | 53 (34–79) | Ia: 34 (26.8%) Ic: 78 (61.4%) II: 15 (11.8%) | None 34 (26.8%) Platinum-based 61 (48.0%) Nonplatinum-based 32 (25.2%) | NA |
| Â | Â | Â | No-LA 36(28.3%) | Not performed | Â | Â | Â | NA |
Kajiyama at el. | 2020 | Japan; 1986–2017 | LA 112(67.5%) | Pelvic and para-aortic lymphadenectomy | 55.0 ± 9.6 | II: 53 (47.3%) III: 52 (46.4%) IV: 7 (6.3%) | None 3 (2.7%) TP 82 (73.2%) Non-TP 27 (24.1%) | 54.0 (5.1– 184.2) |
|  |  |  | No-LA 54(32.5%) | Not performed | 56.5 ± 12.3 | II: 25 (46.3%) III: 23 (42.6%) IV: 6 (11.1%) | None 3 (5.6%) TP 40 (74.1%) Non-TP 11 (20.5%) | 50.4 (1.6–159.8) |
Nasioudis at el. | 2021 | USA; 2010–2015 | LA 52(43.3%) | Pelvic and para-aortic lymphadenectomy | NA | Stage III | NA | 43.63 |
| Â | Â | Â | No-LA 68(56.7%) | Not performed | NA | Â | NA | 53.75 |